Discreet, evidence-based evaluation for vulvovaginal candidiasis from a board-certified provider. Get a prescription sent directly to your pharmacy — no waiting room required.

Board-Certified HIPAA-Compliant Same-Day Available DE · MD · WA

Book a Same-Day Visit →

What Is a Vaginal Yeast Infection?

Vulvovaginal candidiasis (VVC) is a fungal infection of the vagina and vulvar tissues caused most commonly by Candida albicans (accounting for approximately 85–90% of cases), with Candida glabrata and other non-albicans species responsible for most remaining cases. It is one of the most prevalent gynecologic complaints, affecting an estimated 75% of women at least once during their reproductive years. VVC is not classified as a sexually transmitted infection, though sexual activity can sometimes trigger or worsen symptoms.

The pathophysiology involves an overgrowth of Candida yeast that normally colonizes the vagina at low levels. When the normal vaginal microbiome is disrupted — through antibiotic use, hormonal fluctuations, immunosuppression, elevated blood glucose, or other factors — yeast can proliferate beyond the threshold that causes symptoms. Risk factors include recent antibiotic therapy (which depletes protective lactobacilli), uncontrolled or undiagnosed diabetes mellitus, use of oral contraceptives or high-dose estrogen, immunosuppressive conditions or medications (including corticosteroids), pregnancy, and tight-fitting synthetic clothing that retains moisture.

Recurrent vulvovaginal candidiasis (RVVC) is defined as four or more documented episodes per year and represents a distinct clinical challenge requiring a longer-term management strategy. your board-certified provider, provides thorough, non-judgmental evaluation aligned with CDC STI Treatment Guidelines and clinical best practices — entirely via telehealth, serving patients in Delaware, Maryland, and Washington.

Common Symptoms of a Yeast Infection

How Innocre Treats Yeast Infections Online

During your telehealth visit, your provider will conduct a detailed clinical history including symptom onset and character, prior yeast infection diagnoses, recent antibiotic or steroid use, contraceptive method, glucose control in diabetic patients, and any previous treatments — OTC or prescription. Because the classic presentation of Candida albicans VVC (intense pruritus, white clumping discharge, absence of odor) is highly recognizable, clinical diagnosis without microscopy is appropriate in patients with a consistent prior history. For atypical presentations or recurrent cases, a laboratory-confirmed pH and microscopy or culture may be ordered at a local laboratory to guide treatment.

For uncomplicated VVC, first-line treatment options include both OTC topical antifungals and prescription oral azoles. OTC intravaginal options — miconazole (Monistat) or clotrimazole — are effective for mild to moderate episodes and are appropriate to recommend. When prescription therapy is preferred or OTC products have failed, fluconazole 150 mg orally in a single dose is the standard-of-care treatment per CDC guidelines. For cases where C. glabrata or non-albicans species are suspected (often resistant to fluconazole), terconazole vaginal cream or suppositories are a recommended alternative. Boric acid 600 mg vaginal suppositories inserted daily for 14 days is an evidence-supported option for non-albicans VVC and azole-resistant cases, and may be discussed during your visit.

For patients with recurrent VVC (four or more episodes per year), a suppressive maintenance regimen is indicated. This typically involves fluconazole 150 mg weekly for six months following induction therapy. your provider will discuss underlying risk factors, the role of probiotics in restoring vaginal flora, and individualized management strategies. Prescriptions are sent electronically to your preferred pharmacy in DE, MD, or WA.